Ross Douglas T. - 21 Dec 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Reporting relationship: Former CSO
Issuer ticker: OCX
Reported as of: 21 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Dec 2022, 17:57:14 UTC
Prior SEC filing: 20 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Douglas Ross

Key filing fact

Ross Douglas T. filed Form 4 for Oncocyte Corp (OCX) on 22 Dec 2022.

Key facts

This page summarizes Ross Douglas T.'s Form 4 filing for Oncocyte Corp (OCX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Dec 2022, 17:57.

Change

Previous filing in this sequence was filed on 20 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCX transaction

Common Stock, no par value

Award

Transaction value: $0
Shares: +213,797
Change %: +1052%
Price: $0.000000
Shares after: 234,114
Date: 21 Dec 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The restricted stock units will vest as follows: (i) one-third on January 31, 2023, (ii) one-third on February 28, 2023, and (ii) one-third on March 31, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date.